Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Cited by (230)

Items 201–230 of 230

1. Data from Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade
   Julia Boshuizen, Nora Pencheva, Oscar Krijgsman, Daniela M. D'Empaire Altimari, Patricia Garrido Castro, Beaunelle de Bruijn, Maarten Alexander Ligtenberg, Elke Gresnigt-Van den Heuvel, David W. Vredevoogd, Ji‐Ying Song et al. · 2023
2. Data from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
   Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofía Ibáñez Molero, Beaunelle de Bruijn, Paulien Cornelissen‐Steijger, Aida Shahrabi, Martin Del Castillo Velasco‐Herrera et al. · 2023
3. Data from Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4
   Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofía Ibáñez Molero, Beaunelle de Bruijn, Paulien Cornelissen‐Steijger, Aida Shahrabi, Martin Del Castillo Velasco‐Herrera et al. · 2023
4. Data from Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
   Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul Hogg, François Bertelli, Peter J Tyrer, Narinder Janghra, Halla W. Reinert, John Anthony Hartley, Patrick H. van Berkel · 2023
5. Data from Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers
   Francesca Zammarchi, Karin Havenith, Simon Chivers, Paul Hogg, François Bertelli, Peter J Tyrer, Narinder Janghra, Halla W. Reinert, John Anthony Hartley, Patrick H. van Berkel · 2023
6. Data from AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer
   Wenting Du, Natalie Z. Phinney, Huocong Huang, Zhaoning Wang, Jill M. Westcott, Jason E. Toombs, Yuqing Zhang, Muhammad Shaalan Beg, Thomas Martin Wilkie, James B. Lorens et al. · 2023
7. Data from AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors
   Kavya Ramkumar, Catherine Allison Stewart, Kasey R. Cargill, Carminia Maria Della Corte, Qi Wang, Li Shen, Lixia Diao, Robert J. Cardnell, David H. Peng, B. Leticia Rodriguez et al. · 2023
8. Cooperativity in melanoma metastasis
   Mei Fong Ng · 2023 · Queensland University of Technology
9. Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications
   Sutapa Sinha, Ray Guo, Miles D. Del Busso, Weiguo Han, Justin C. Boysen, Linda E. Wellik, Asish K. Ghosh, Neil E. Kay · 2024 · British Journal of Cancer
10. Circular RNA circ_0001591 Contributes to Melanoma Cell Migration Through AXL and FRA1 Proteins by Targeting miR-20a-3p and miR-34a-5p
    Elisa Orlandi, Elisa De Tomi, Francesca Belpinati, Marta Menegazzi, Macarena Gomez‐Lira, Maria Grazia Romanelli, Elisabetta Trabetti · 2025 · Genes
11. Additional file 2 of Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
    Sandra Goetze, Audrey van Drogen, Jonas B. Albinus, Kyle L. Fort, Tejas Gandhi, Damiano Robbiani, Véronique Laforte, Lukas Reiter, Mitchell Paul Levesque, Yue Xuan et al. · 2024 · Figshare
12. Additional file 1 of Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
    Sandra Goetze, Audrey van Drogen, Jonas B. Albinus, Kyle L. Fort, Tejas Gandhi, Damiano Robbiani, Véronique Laforte, Lukas Reiter, Mitchell Paul Levesque, Yue Xuan et al. · 2024 · Figshare
13. Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment
    Vito W. Rebecca, Min Xiao, Andrew V. Kossenkov, Tetiana Godok, Gregory Schuyler Brown, Dylan Fingerman, Gretchen Marie Alicea, Meihan Wei, Hongkai Ji, Marie Elena Portuallo et al. · 2026 · iScience
14. AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma
    Rupesh Paudel, Simon G. Goller, Stefanie Schwarz, Katharina Meder, M-E Goebeler, Marc Schmidt · 2026 · Neoplasia
15. AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers
    Masaki Ishida, Tadaaki Yamada, Yuki Katayama, Hayato Kawachi, Ryo Sawada, Ryota Nakamura, Soichi Hirai, Yohei Matsui, Kenji Morimoto, Keisuke Onoi et al. · 2026 · npj Precision Oncology
16. Mécanismes de résistance aux thérapies ciblées du mélanome : implication du facteur de transcription Aryl hydrocarbon Receptor
    Nina Tardif · 2019 · theses.fr (ABES)
17. Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
    Arthur Gautron · 2019 · theses.fr (ABES)
18. Role of SWI/SNF chromatin-remodeling complexes in tumorigenesis : insights in dedifferentiated melanoma and renal medullary carcinoma
    Bujamin Vokshi · 2020
19. Rôle de c-Jun dans la réponse aux inhibiteurs de la voie des MAPK dans les mélanomes
    Magdalena Pohorecka · 2018 · theses.fr (ABES)
20. Mécanismes moléculaires et cellulaires de formation et de dissolution des « processing bodies » en conditions physiologiques et physiopathologiques
    Olivia Vidal-Cruchez · 2021 · theses.fr (ABES)
21. The pro-fibrotic miR-143/145 cluster promotes mesenchymal phenotypic plasticity associated with resistance to targeted therapies in melanoma
    Serena Diazzi · 2021 · theses.fr (ABES)
22. Rôle de l'enzyme LOXL2 dans le comportement pro-invasif des cellules de mélanome et le remodelage matriciel du stroma tumoral
    Alexandrine Carminati · 2023 · theses.fr (ABES)
23. FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma
    Marwan Almoiliqy, Peng Li, Young-Ho Jung, Dorothy Zheng, Abeer Alshambky, Mohamad Karim Koleilat, Michael A. Davies, Lawrence N. Kwong · 2026 · Cell Death Discovery
24. MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming
    Monika Kisielewska, Sara Suwała, Małgorzata Drąg‐Zalesińska, Nina Rembiałkowska · 2026 · Cell Cycle
25. Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response
    Yueqiong Lao, Jie Yang, Minli Hu, Jing Li, Weikang Xu, Jiahui Xu, Huan Wang, Hechenhao Jiang, Zhihao Pei, Xinyi Qiu et al. · 2026 · iScience
26. Transcriptional Reprogramming by AP-1-Bound Cis-Regulatory Elements Is Associated with Melanoma Development
    Zubeir El Ahmad, Katrin Ludwig, Alexander O. Matthies, Anja‐Katrin Bosserhoff, Melanie Kappelmann‐Fenzl · 2026 · International Journal of Molecular Sciences
27. Advancing antibody drug conjugates in gastrointestinal cancers
    Philippe Alexandre Cassier, Floriane Izarn, Charles Dumontet, Clélia Coutzac · 2026 · British Journal of Cancer
28. Single-Cell RNA-Sequencing Reveals Tumor Microenvironment Composition and Prior Therapy Modulate Response to Axl Inhibition
    Anisha Datta, Kate Bridges, Remziye E. Wessel, Hratch Baghdassarian, Laura C. Bahlmann, Diana N. Gong, Erin N. Tevonian, Brian A. Joughin, Douglas A. Lauffenburger · 2026 · Cellular and Molecular Bioengineering
29. AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer
    Holly L. Hoffman, Kate M. Von Handorf, Catherine A. Behrmann, Justin Durla Lathia, David R. Plas · 2026 · iScience
30. Targeting the untargeted: Emerging targeted therapies in metastatic melanoma beyond BRAF/MEK inhibitors
    M.-E. Dimitrakopoulou, Charalampos Theocharopoulos, Aikaterini Katsandri, Dimitra Foteinou, Dimitra T. Stefanou, Aikaterini Gkoufa, Konstantinos Tsoukalas, Thalia Bousou, Amalia N. Anastasopoulou, Helen Gogas et al. · 2026 · Critical Reviews in Oncology/Hematology